Citi analyst Carly Kenselaar maintained a Buy rating on Travere Therapeutics, raising the stock’s price target from $31 to $35. Kenselaar’s optimism is based on anticipated regulatory ...
Citi analyst Carly Kenselaar maintained a Buy rating on Travere Therapeutics, raising the stock’s price target from $31 to $35. Kenselaar’s optimism is based on anticipated regulatory developments for ...
After hours: March 20 at 7:49:20 PM EDT Loading Chart for RL ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback